White D - Search Results

1

High-risk B-cell acute lymphoblastic leukaemia presenting with hypereosinophilia and acquiring a novel PAX5 fusion on relapse.

McClure BJ, Heatley SL, Rehn J, Breen J, Sutton R, Hughes TP, Suppiah R, Revesz T, Osborn M, White D, Yeung DT, White DL. McClure BJ, et al. Among authors: white d, white dl. Br J Haematol. 2020 Oct;191(2):301-304. doi: 10.1111/bjh.17002. Epub 2020 Jul 30. Br J Haematol. 2020. PMID: 32731299 Free article. No abstract available.

2

Direct analysis of FACS-sorted hemopoietic cell fractions using FISH.

White DL, Hutchins CJ, Haylock DN, Turczynowicz S, Bishop A, To LB, Hughes TP, Juttner CA. White DL, et al. Biotechniques. 1995 May;18(5):818, 820-1. Biotechniques. 1995. PMID: 7542458 No abstract available.

3

Apoptosis regulatory gene NEDD2 maps to human chromosome segment 7q34-35, a region frequently affected in haematological neoplasms.

Kumar S, White DL, Takai S, Turczynowicz S, Juttner CA, Hughes TP. Kumar S, et al. Among authors: white dl. Hum Genet. 1995 Jun;95(6):641-4. doi: 10.1007/BF00209480. Hum Genet. 1995. PMID: 7789948

4

Detection of minimal residual disease in an AML patient with trisomy 8 using interphase fish.

White DL, Hutchins CJ, Turczynowicz S, Suttle J, Haylock DN, Hughes TP, Juttner CA, To LB. White DL, et al. Pathology. 1997 Aug;29(3):289-93. doi: 10.1080/00313029700169115. Pathology. 1997. PMID: 9271020

5

Selected CD34 blood cell allografts for older patients: low transplant-related mortality, graft failure and acute GvHD.

Roberts MM, Dyson P, Rawling C, Thorp D, Rawling T, White D, Horvath N, Bardy P, Hui CH, Dart GW, To LB, Hughes TP. Roberts MM, et al. Among authors: white d. Cytotherapy. 2003;5(6):534-41. doi: 10.1080/14653240310003594. Cytotherapy. 2003. PMID: 14660049 Clinical Trial.

6

In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML.

White D, Saunders V, Lyons AB, Branford S, Grigg A, To LB, Hughes T. White D, et al. Blood. 2005 Oct 1;106(7):2520-6. doi: 10.1182/blood-2005-03-1103. Epub 2005 Jun 14. Blood. 2005. PMID: 15956284 Free article.

7

OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib.

White DL, Saunders VA, Dang P, Engler J, Zannettino AC, Cambareri AC, Quinn SR, Manley PW, Hughes TP. White DL, et al. Blood. 2006 Jul 15;108(2):697-704. doi: 10.1182/blood-2005-11-4687. Epub 2006 Apr 4. Blood. 2006. PMID: 16597591 Free article.

8

Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs.

White DL, Saunders VA, Quinn SR, Manley PW, Hughes TP. White DL, et al. Blood. 2007 Apr 15;109(8):3609-10. doi: 10.1182/blood-2006-11-058032. Blood. 2007. PMID: 17409347 Free article. No abstract available.

9

Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia.

White D, Saunders V, Grigg A, Arthur C, Filshie R, Leahy MF, Lynch K, To LB, Hughes T. White D, et al. J Clin Oncol. 2007 Oct 1;25(28):4445-51. doi: 10.1200/JCO.2006.09.9499. J Clin Oncol. 2007. PMID: 17906206

10

BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros.

Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, White D, Hughes TP, Le Beau MM, Pui CH, Relling MV, Shurtleff SA, Downing JR. Mullighan CG, et al. Among authors: white d. Nature. 2008 May 1;453(7191):110-4. doi: 10.1038/nature06866. Epub 2008 Apr 13. Nature. 2008. PMID: 18408710

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,066 results

Search Page

Filters